AKESO INC. O.N. - Asset Resilience Ratio
AKESO INC. O.N. (4RY) has an Asset Resilience Ratio of 2.18% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See AKESO INC. O.N. short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how AKESO INC. O.N.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see AKESO INC. O.N. balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down AKESO INC. O.N.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read AKESO INC. O.N. total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €349.21 Million | 2.18% |
| Total Liquid Assets | €349.21 Million | 2.18% |
Asset Resilience Insights
- Limited Liquidity: AKESO INC. O.N. maintains only 2.18% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
AKESO INC. O.N. Industry Peers by Asset Resilience Ratio
Compare AKESO INC. O.N.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for AKESO INC. O.N. (2022–2025)
The table below shows the annual Asset Resilience Ratio data for AKESO INC. O.N..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.18% | €349.21 Million ≈ $408.27 Million |
€16.00 Billion ≈ $18.71 Billion |
-1.16pp |
| 2024-12-31 | 3.34% | €425.79 Million ≈ $497.79 Million |
€12.75 Billion ≈ $14.91 Billion |
-5.95pp |
| 2023-12-31 | 9.28% | €852.43 Million ≈ $996.58 Million |
€9.18 Billion ≈ $10.73 Billion |
+5.72pp |
| 2022-12-31 | 3.56% | €195.91 Million ≈ $229.04 Million |
€5.50 Billion ≈ $6.43 Billion |
-- |
About AKESO INC. O.N.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell car… Read more